Evaxion Launches EVX-05 Glioblastoma Vaccine, Ends EVX-03
EVAX sits 33% above its 52-week low of $2.52.
Summary
Evaxion announced a new glioblastoma vaccine program, EVX-05, in collaboration with Duke University, and discontinued its EVX-03 program. Cash runway remains intact into H2 2027.
Key Events · Product Development and Regulatory · EVAX
-
New EVX-05 Glioblastoma Program
Evaxion announced EVX-05, an off-the-shelf therapeutic vaccine for glioblastoma, designed using its AI-Immunology platform to target endogenous retrovirus antigens.
-
Duke University Collaboration
The company is collaborating with Duke University School of Medicine, with initial clinical testing expected to be conducted by Professor Khasraw's team.
-
EVX-03 Discontinued
Evaxion discontinued its EVX-03 program as part of portfolio management, refocusing R&D efforts on EVX-05 and other programs.
-
Cash Runway Maintained
The company reiterated its cash runway extends into the second half of 2027, with EVX-05 costs absorbed within existing budgets.
Analysis · EVAX · Life Sciences
A new off-the-shelf brain cancer vaccine program, EVX-05, targeting glioblastoma, has been announced in collaboration with Duke University. The program leverages the company's AI-Immunology platform to target endogenous retrovirus antigens. As part of portfolio refocusing, the EVX-03 program was discontinued, while the cash runway remains intact into the second half of 2027. For a clinical-stage biotech with a market cap of approximately $28 million, this is a meaningful pipeline update.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, EVAX was trading at $3.34 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $27.9M. The 52-week trading range was $2.52 to $12.15. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.